Today, RaySearch Laboratories AB (publ) publishes its Annual Report for the financial year 2022. The report is held available on RaySearch’s website, under the section Investors.
This information is information that RaySearch Larboratiories AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication at 08:30 am CET, on April 28, 2023.
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch software has been sold to more than 900 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
* Subject to regulatory clearance in some markets.
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com
Henrik Bergentoft, CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
henrik.bergentoft@raysearchlabs.com